GlassScriptPhysician profile
Amanda A Reeves
NPI 1609062355
$2,156.02
in general payments reported to CMS, 2019-2025
27 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $130 · 2021: $715 · 2022: $189 · 2023: $364 · 2024: $371 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.17 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.82 | 2019-2023 | |
| Astellas Pharma US INC | $226.37 | 2021-2025 | Veozah |
| Hologic Sales and Service, LLC | $176.17 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Aptima |
| Gynesonics, INC. | $143.53 | 2021 | |
| Mayne Pharma Commercial LLC | $125.06 | 2021-2025 | |
| Organon LLC | $99.50 | 2022-2025 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $78.36 | 2021 | |
| Pfizer INC. | $74.54 | 2019-2025 | |
| Lilly USA, LLC | $63.01 | 2025 | Zepbound |
| Amgen INC. | $59.64 | 2019-2022 | |
| Daiichi Sankyo INC. | $36.06 | 2021-2022 | |
| Sage Therapeutics, LLC | $28.75 | 2025 | Zurzuvae |
| Channel Medsystems, INC. | $25.36 | 2024-2025 | |
| Shield Therapeutics INC | $25.00 | 2024 | |
| Exeltis, USA INC. | $24.72 | 2024 | Slynd |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $23.02 | 2019 | |
| Vertical Pharmaceuticals, LLC | $21.77 | 2019 | |
| Innovation Technologies INC | $19.90 | 2024 | Irrisept |
| Bayer Healthcare Pharmaceuticals INC. | $16.48 | 2023 | |
| Smith+Nephew, INC. | $14.39 | 2024 | Pico 7 |
| Therapeuticsmd, INC. | $13.68 | 2021 | |
| Novo Nordisk INC | $13.34 | 2024 | Wegovy, Saxenda |
| Radius Health, INC. | $12.50 | 2021 | |
| Avanos Medical | $12.42 | 2019 | |
| Myovant Sciences INC. | $12.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.95 | 2022 | |
| Aspira Women'S Health INC | $11.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.